Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer.

While patients with a HER2-enriched subtype achieved a highly significant benefit from being assigned to CEF, this study cannot fully address to what extent those with a Basal-like or a Luminal B subtype benefitted.

also in 132,142 other papers